1. Home
  2. ELTX vs SNCR Comparison

ELTX vs SNCR Comparison

Compare ELTX & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELTX
  • SNCR
  • Stock Information
  • Founded
  • ELTX 2011
  • SNCR 2000
  • Country
  • ELTX United States
  • SNCR United States
  • Employees
  • ELTX N/A
  • SNCR N/A
  • Industry
  • ELTX Biotechnology: Pharmaceutical Preparations
  • SNCR EDP Services
  • Sector
  • ELTX Health Care
  • SNCR Technology
  • Exchange
  • ELTX Nasdaq
  • SNCR Nasdaq
  • Market Cap
  • ELTX 49.7M
  • SNCR 137.5M
  • IPO Year
  • ELTX 2021
  • SNCR 2006
  • Fundamental
  • Price
  • ELTX $4.16
  • SNCR $11.25
  • Analyst Decision
  • ELTX Buy
  • SNCR
  • Analyst Count
  • ELTX 2
  • SNCR 0
  • Target Price
  • ELTX $10.00
  • SNCR N/A
  • AVG Volume (30 Days)
  • ELTX 16.1K
  • SNCR 81.2K
  • Earning Date
  • ELTX 11-07-2024
  • SNCR 11-12-2024
  • Dividend Yield
  • ELTX N/A
  • SNCR N/A
  • EPS Growth
  • ELTX N/A
  • SNCR N/A
  • EPS
  • ELTX N/A
  • SNCR N/A
  • Revenue
  • ELTX N/A
  • SNCR $167,615,000.00
  • Revenue This Year
  • ELTX N/A
  • SNCR $7.76
  • Revenue Next Year
  • ELTX N/A
  • SNCR $5.83
  • P/E Ratio
  • ELTX N/A
  • SNCR N/A
  • Revenue Growth
  • ELTX N/A
  • SNCR 33.39
  • 52 Week Low
  • ELTX $2.96
  • SNCR $2.70
  • 52 Week High
  • ELTX $11.45
  • SNCR $15.46
  • Technical
  • Relative Strength Index (RSI)
  • ELTX 40.82
  • SNCR 43.11
  • Support Level
  • ELTX $4.05
  • SNCR $10.45
  • Resistance Level
  • ELTX $4.89
  • SNCR $11.44
  • Average True Range (ATR)
  • ELTX 0.28
  • SNCR 0.57
  • MACD
  • ELTX -0.06
  • SNCR -0.06
  • Stochastic Oscillator
  • ELTX 27.37
  • SNCR 31.58

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a leading provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and highly scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

Share on Social Networks: